# Lychee Seed Extract Targets Proliferation, Differentiation, and Cell Cycle Proteins to Suppress Human Colorectal Tumor Growth in Xenograft Models

**Authors:** Szu-Nian Yang, Yi-Ping Chang, Oscar C. Y. Yang, Chi-Sheng Wu, Chiu-Chen Huang, Jia-Feng Chang, Chia-Ming Liang, Shun-Tai Dai, Lung Chen, Chih-Ping Hsu

PMC · DOI: 10.3390/ijms26199786 · 2025-10-08

## TL;DR

Lychee seed extract shows anti-cancer effects in colorectal tumor models by targeting proteins involved in cell growth and division.

## Contribution

LCSE demonstrates in vivo anti-tumor activity in CRC xenografts through non-apoptotic mechanisms.

## Key findings

- LCSE significantly inhibited tumor growth in HT-29 xenografts and reduced key proliferation markers.
- In SW480 tumors, LCSE showed inhibitory effects at higher doses with limited impact on p53.
- No systemic toxicity was observed in mice treated with LCSE.

## Abstract

Colorectal cancer (CRC) remains a leading global health challenge, and natural products are increasingly explored for their multi-targeted therapeutic potential. Litchi chinensis seed extract (LCSE) has shown promising anti-cancer activity in vitro, though its in vivo effects remain underexplored. LCSE was analyzed by colorimetric assays and HPLC to quantify the phytochemical composition. Nude mice bearing HT-29 or SW480 xenografts were orally administered LCSE (0.1 or 0.6 g/kg) daily for 14 days. Tumor volume was measured, and immunohistochemistry was used to assess EGFR, p21, p53, Ki-67, CEA, CK20, CDX2, and Bax expression. Phytochemical profiling demonstrated LCSE contains abundant phenolics and flavonoids, with gallic acid as a predominant constituent, underscoring the potential bioactive properties. LCSE significantly inhibited tumor growth in HT-29 xenografts and dose-dependently reduced EGFR, p21, p53, cell cycle proteins and proliferation/differentiation markers. In SW480 tumors, inhibitory effects were evident primarily at the higher dose, with limited reduction in p53 expression. Bax levels remained unchanged in both models, indicating a non-apoptotic mechanism. No systemic toxicity was observed in treated mice. LCSE exhibits dose-dependent anti-tumor activity in CRC xenografts, likely mediated through suppression of proliferation and modulation of key regulatory proteins rather than apoptosis. These findings support LCSE as a safe, multi-target botanical candidate for CRC intervention and justify further mechanistic and translational studies.

## Linked entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], TP53 (tumor protein p53) [NCBI Gene 7157], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345], CEACAM5 (CEA cell adhesion molecule 5) [NCBI Gene 1048], KRT20 (keratin 20) [NCBI Gene 54474], CDX2 (caudal type homeobox 2) [NCBI Gene 1045], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581]
- **Chemicals:** gallic acid (PubChem CID 370)
- **Diseases:** colorectal cancer (MONDO:0005575), CRC (MONDO:0005575)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** CRC (MESH:D015179), toxicity (MESH:D064420), Tumor (MESH:D009369)
- **Chemicals:** gallic acid (MESH:D005707), LCSE (-), flavonoids (MESH:D005419)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12524773/full.md

---
Source: https://tomesphere.com/paper/PMC12524773